Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies.
about
A Computationally Designed Hemagglutinin Stem-Binding Protein Provides In Vivo Protection from Influenza Independent of a Host Immune ResponseProphylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus.Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)-Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection.Monoclonal antibody therapy for Junin virus infection.Preserved antiviral adaptive immunity following polyclonal antibody immunotherapy for severe murine influenza infection.Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy VolunteersAerosol administration increases the efficacy of oseltamivir for the treatment of mice infected with influenza viruses.An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody protects mice from morbidity without interfering with the development of protective immunity to subsequent homologous challenge.Reprogramming the lung microenvironment by inhaled immunotherapy fosters immune destruction of tumor.Native Human Monoclonal Antibodies with Potent Cross-Lineage Neutralization of Influenza B Viruses.Therapeutic Administration of Broadly Neutralizing FI6 Antibody Reveals Lack of Interaction Between Human IgG1 and Pig Fc Receptors.
P2860
Q28553101-087DF619-239C-43E0-AB2F-93D6E6B86DACQ35989939-1147FAF0-DB8F-4282-917A-3859C5E5D665Q36816625-5E643A06-FA6A-41F1-8930-D4ED4DD8DA17Q36831453-484E33BE-432A-415D-9F6D-94E8F5FAE122Q37067663-1E2E8FDB-2D19-4E70-BB2A-409E45BD1B99Q37203832-BC2EE71D-E2A1-4D19-AC50-13B742BA0899Q38912274-786531AD-1435-4735-89FF-B81F2793264FQ40049822-803C885A-6C21-4106-A792-6E3A0407C41EQ41716739-7B8BF591-B68A-4404-8443-F8FBC9E44C51Q52673291-B6245D0D-DCBB-4356-94BE-47CF24EA2090Q54217589-DF1AF91A-E7E5-41DD-9B14-585ECF2EAABE
P2860
Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Direct administration in the r ...... a virus monoclonal antibodies.
@ast
Direct administration in the r ...... a virus monoclonal antibodies.
@en
type
label
Direct administration in the r ...... a virus monoclonal antibodies.
@ast
Direct administration in the r ...... a virus monoclonal antibodies.
@en
prefLabel
Direct administration in the r ...... a virus monoclonal antibodies.
@ast
Direct administration in the r ...... a virus monoclonal antibodies.
@en
P2860
P50
P356
P1476
Direct administration in the r ...... a virus monoclonal antibodies.
@en
P2093
Mark Yondola
Paul E Leon
P2860
P304
P356
10.1128/AAC.00290-15
P407
P577
2015-05-04T00:00:00Z